Compare Coupang Inc (CPNG) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Nuwellis Inc — how do they compare? Coupang Inc trades at $17.77 (market cap $32.17B), while Nuwellis Inc trades at $3.26 (market cap $1.17M). The key difference: Coupang Inc is far larger — about 27495.7× Nuwellis Inc's market cap, and Coupang Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| CPNG | NUWE | |
|---|---|---|
Market Cap | $32.17B | $1.17M |
Sector | Consumer Cyclical | Technology |
52-Week High | $33.53 | $558.26 |
52-Week Low | $15.12 | $2.80 |
Enterprise Value | $31.26B | -$636.97K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $17.92, down 4.68% today, with a bearish technical signal and mixed earnings. Revenue grew to $34.53B in 2025, but net income margin is negative at -0.47%. Recent news includes a $412M fine for a data breach in South Korea (Reuters, 2026-06-11). The stock faces regulatory headwinds but maintains strong analyst support with an 87.5% buy rating and a $25.80 consensus target.
Outlook: CPNG offers growth potential from e-commerce expansion but carries risks from regulatory fines and profitability challenges. Investors should weigh strong cash flow against recent earnings misses and legal issues. The stock's current price is 30% below the consensus target, presenting upside if execution improves.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
